The FDA on Sept. 25 approved Juvmo (tavapadon), a once-daily pill from AbbVie, to treat Parkinson's disease in adults, according to the agency's 2026 list of novel drug approvals. Nausea, dizziness, and headache were among the most common side effects reported in clinical trials.
AbbVie did not disclose a price or launch date, Reuters reported. According to the same report, Citi analysts had expected a third-quarter 2026 launch, with gradual uptake as Medicare coverage is negotiated.
For patients and caregivers, the approval adds a treatment option rather than a replacement. Juvmo treats symptoms. It does not slow the disease, restore the brain's dopamine production, or replace lost nerve cells, and it was tested against placebo, not head-to-head against levodopa or older drugs in its class.
A Dopamine Agonist Aimed at Different Receptors
Parkinson's disease is a progressive brain disorder that develops as dopamine-producing cells are lost, often causing tremor, stiffness, slowed movement, and balance problems. More than 11 million people worldwide live with the disease, according to AbbVie.
Dopamine agonists are drugs that mimic dopamine by acting directly on its receptors. Older agonists, such as pramipexole and ropinirole, mainly act on receptors called D2 and D3. Juvmo is a partial agonist at D1 and D5 receptors, which play a key role in the brain's movement circuits. The goal is to keep the movement benefits of a dopamine agonist while lowering the risk of side effects linked to D2 and D3 activity.
Dr. Hubert Fernandez, director of the Center for Neurological Restoration at Cleveland Clinic, was the global principal investigator of two of the company's phase 3 trials, TEMPO-2 and TEMPO-3. He described the concerns with older agonists in a Cleveland Clinic report on the TEMPO trials. "These were excessive daytime sleepiness, in particular sleep attacks, in which patients fall asleep suddenly, as well as impulse control behavior disorders such as obsessive gambling, shopping, eating and hypersexuality," he said.
He added that the newer approach is not risk-free. "D1-targeting drugs are not exempt, but the representation of adverse effects of interest was much higher with D2 agonists," Fernandez said.
Side Effects and Results from the TEMPO Trials
The approval rests on the phase 3 TEMPO program. In TEMPO-1, which enrolled 529 adults with early Parkinson's disease, patients taking Juvmo alone improved by 11.5 points at the 5 mg dose and 12.1 points at the 15 mg dose compared with placebo on a standard scale of motor symptoms and daily activities, according to the TEMPO-1 results in JAMA Neurology. Adverse events led 64 of the 354 patients on the drug (18.1%) to stop treatment, compared with 7 of 175 on placebo (4.0%), according to Healio's report on the study.
TEMPO-2, published in The Lancet Neurology, enrolled 304 adults who had been diagnosed within the previous three years. The most common side effects with Juvmo were nausea (30%), headache (17%), and dizziness (16%). Serious adverse events that emerged during treatment occurred in 4.6% of patients on the drug and 1.3% of those on placebo, according to the Cleveland Clinic report.
In TEMPO-3, also published in JAMA Neurology, Juvmo was added to levodopa in 507 patients whose symptoms fluctuated during the day. It increased daily "on" time, when symptoms are well controlled, without troublesome dyskinesia by about 1.1 hours compared with placebo. Dyskinesia means involuntary movements. Nausea, dyskinesia, and dizziness were the most common side effects.
MedicalDaily Evidence Check: These were randomized, placebo-controlled trials sponsored by the drug's developer, each lasting about six months. They show symptom improvement and short-term safety, but not long-term safety or superiority over existing medicines. A longer, open-label extension study called TEMPO-4, in which all participants receive the drug, has reported interim results but has no placebo group for comparison. The FDA directs patients and clinicians to the drug's prescribing information on Drugs@FDA for its full approved conditions of use.
Questions to Ask Before Adding or Switching a Pill
The people most likely to discuss Juvmo with a neurologist are adults with early Parkinson's disease who want to delay or limit levodopa, and people already on levodopa who have "off" periods when symptoms return. Fernandez noted that levodopa usually starts at three times a day and often ends up being taken four to seven times a day, which is why a once-daily option may matter to people with a heavy pill schedule.
Older adults prone to falls should ask how dizziness and blood pressure changes will be monitored. Anyone who drives should ask about daytime sleepiness, a known concern with dopamine-based treatments. Patients with a history of compulsive behaviors, hallucinations, or heart problems should share that history before starting.
Patients should not stop or reduce their current Parkinson's medicines without a clinician's guidance, since abrupt changes can worsen symptoms. Warning signs worth reporting include new falls, fainting, sudden sleep episodes, hallucinations, confusion, and urges to gamble, shop, or eat compulsively. Chest pain, severe confusion, or a fall with a head injury needs urgent medical attention.
Cost may be the biggest practical hurdle. Generic dopamine agonists and levodopa are widely available at low cost, while Juvmo's price has not been disclosed. Patients can ask their neurologist about prior authorization, whether their Medicare Part D or other drug plan will cover Juvmo once it launches, and any manufacturer assistance program. Caregivers may want to keep a log of symptoms and side effects during the first weeks of any new treatment to bring to follow-up visits.
The next milestones are AbbVie's pricing announcement, the drug's commercial launch, insurance and Medicare coverage decisions, and longer-term data from the extension study.
Key Questions Answered
What is Juvmo? Juvmo (tavapadon) is a once-daily oral medicine from AbbVie that the FDA approved on Sept. 25, 2026, to treat Parkinson's disease in adults.
How does it work? It is a dopamine agonist that partially activates D1 and D5 dopamine receptors, mimicking dopamine's effect in the brain's movement circuits.
What side effects were reported? Nausea, dizziness, and headache were common in trials, and dyskinesia (involuntary movement) was common when the drug was added to levodopa.
Is Juvmo a cure? No. It treats symptoms and does not slow the disease. It has not been compared directly with levodopa or older dopamine agonists.
How much will it cost? AbbVie has not disclosed a price. Citi analysts had expected gradual uptake as Medicare coverage is negotiated, Reuters reported.
Should patients switch from their current medicine? Not without a clinician's guidance. Any change should be planned with a neurologist, since abrupt changes can worsen symptoms.
Published by Medicaldaily.com
